Concepedia

Rafał Wojciechowski

RW

4

Publications

416

Citations

4

H-Index

2018

Active since

Affiliations

University of Washington(Current)

University of Massachusetts Chan Medical School

University of California, Los Angeles

University of Toronto

University of Warmia and Mazury in Olsztyn

Rafał Wojciechowski is an author at University of Washington specializing in orthopaedics, spondyloarthritis, and rheumatology.

ORCID

Top concepts

Publications per year

2018–2021

4

Publications

4

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

, , +14

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Jonathan Kay, Janusz Jaworski, Rafał Wojciechowski et al. · Arthritis Research & Therapy · 2021 · 30 citations · Full text

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Mark C. Genovese, Juan Sánchez‐Bursón, Myungshin Oh et al. · Arthritis Research & Therapy · 2020 · 19 citations · Full text

Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg/ml): 52-week randomized, double-blind study in rheumatoid arthritis

Daniel E. Furst, Janusz Jaworski, Rafał Wojciechowski et al. · Lara D. Veeken · 2021 · 18 citations · Full text

Rows per page

1–4 of 4